Immatics NV (IMTX) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Immatics NV

NASDAQ | IMTX

3.84

USD

-0.33 (-7.91%)

AT CLOSE (AS OF Apr 3, 2025)

$507M

MARKET CAP

27.8

P/E Ratio

0.15

EPS

$14

52 Week High

$3.9

52 Week Low

LIFE SCIENCES

Sector

IMTX Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

IMTX Technicals

Tags:

IMTX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field	Value (EUR)
Gross Profit	$156M
Total Revenue	$156M
Cost Of Revenue	-
Costof Goods And Services Sold	-
Operating Income	-$39M
Selling General And Administrative	$46M
Research And Development	$148M
Operating Expenses	$194M
Investment Income Net	-
Net Interest Income	$24M
Interest Income	$25M
Interest Expense	$886K
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$12M
Income Before Tax	$21M
Income Tax Expense	$6.1M
Interest And Debt Expense	-
Net Income From Continuing Operations	$15M
Comprehensive Income Net Of Tax	-
Ebit	$22M
Ebitda	$34M
Net Income	$15M

Revenue & Profitability

Earnings Performance

IMTX Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2024)

Field	Value (EUR)
Total Assets	$696M
Total Current Assets	$630M
Cash And Cash Equivalents At Carrying Value	$237M
Cash And Short Term Investments	$237M
Inventory	-
Current Net Receivables	-
Total Non Current Assets	$67M
Property Plant Equipment	-
Accumulated Depreciation Amortization Ppe	-
Intangible Assets	$1.6M
Intangible Assets Excluding Goodwill	$1.6M
Goodwill	-
Investments	-
Long Term Investments	-
Short Term Investments	$368M
Other Current Assets	$18M
Other Non Current Assets	-
Total Liabilities	$121M
Total Current Liabilities	$68M
Current Accounts Payable	-
Deferred Revenue	-
Current Debt	-
Short Term Debt	$2.9M
Total Non Current Liabilities	$53M
Capital Lease Obligations	$16M
Long Term Debt	-
Current Long Term Debt	-
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$16M
Other Current Liabilities	$15M
Other Non Current Liabilities	-
Total Shareholder Equity	$575M
Treasury Stock	-
Retained Earnings	-$590M
Common Stock	$1.2M
Common Stock Shares Outstanding	$107M

yearly Cash Flow (As of Dec 31, 2024)

Field	Value (EUR)
Operating Cashflow	-$158M
Payments For Operating Activities	-
Proceeds From Operating Activities	-
Change In Operating Liabilities	-
Change In Operating Assets	-
Depreciation Depletion And Amortization	$12M
Capital Expenditures	$16M
Change In Receivables	-
Change In Inventory	-
Profit Loss	-
Cashflow From Investment	-
Cashflow From Financing	$320M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	-
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	$15M

yearly Income Statement (As of Dec 31, 2024)

Field	Value (EUR)
Gross Profit	$156M
Total Revenue	$156M
Cost Of Revenue	-
Costof Goods And Services Sold	-
Operating Income	-$39M
Selling General And Administrative	$46M
Research And Development	$148M
Operating Expenses	$194M
Investment Income Net	-
Net Interest Income	$24M
Interest Income	$25M
Interest Expense	$886K
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$12M
Income Before Tax	$21M
Income Tax Expense	$6.1M
Interest And Debt Expense	-
Net Income From Continuing Operations	$15M
Comprehensive Income Net Of Tax	-
Ebit	$22M
Ebitda	$34M
Net Income	$15M

IMTX Profile

Immatics NV Profile

Sector: LIFE SCIENCES

Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies for the treatment of cancer in the United States. The company is headquartered in Tbingen, Germany.

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.02	13.04%	-	706,860,781
NVDA	$103.14	-6.59%	$2.68T	263,349,217
F	$9.55	-5.96%	$39.53B	213,326,329
LCID	$2.32	-3.33%	$7.67B	210,875,217
PTIX	$0.43	91.50%	$4.04M	173,208,693

Symbol	Price	Change %	Market Cap	Volume
JNJ	$160.56	3.35%	$399.65B	9,908,361
PG	$172.57	1.81%	$399.61B	6,993,394
NVO	$67.12	-1.65%	$308.32B	8,797,694
AZN	$74.03	2.50%	$225.70B	6,150,517
MRK	$86.38	-0.25%	$220.07B	12,113,104

Symbol	Price	Change %	Market Cap	Volume
VCIG	$6.06	1,818.33%	$26.40M	302,396
MKTW	$9.19	1,684.81%	$19.91M	117,875
ICCT	$4.38	111.59%	$9.78M	168,784,937
PTIX	$0.43	91.50%	$4.04M	173,208,693
MRM	$0.65	74.84%	$2.91M	51,693,935

Symbol	Price	Change %	Market Cap	Volume
ALDX	$1.42	-73.33%	$326.91M	21,865,554
RFAC	$2.70	-68.60%	$8.44M	605,339
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
OMQS	$0.04	-66.36%	$1.50M	950,669

Quick Links

IMTX $3.84 (-7.91%) Quote details